Lung Cancer Registry

Launched by ARBEITSGEMEINSCHAFT MEDIKAMENTOESE TUMORTHERAPIE · Dec 3, 2020

Keywords

ClinConnect Summary

**Lung Cancer Registry Trial Summary**

This clinical trial, called the Lung Cancer Registry, aims to gather important information about patients with lung cancer, specifically those with advanced stages of two types: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Lung cancer is a serious disease that affects many people in Austria, and this study seeks to improve our understanding of how to treat it better. Researchers are particularly interested in exploring how different treatments work for patients who have specific characteristics of their cancer, especially since there are many types of NSCLC that may respond differently to treatment.

To participate in this trial, you need to be at least 18 years old and diagnosed with either stage III or stage IV non-small cell lung cancer, or have small cell lung cancer that is limited or extensive. There are no specific exclusion criteria, which means that almost anyone who meets these conditions can join. If you decide to participate, you’ll be part of a study that helps researchers gather data that could lead to better treatment options in the future. Your involvement could contribute to the development of more personalized care for lung cancer patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • stage III A-C and IV A-B NSCLC
• • limited disease (LD) and extensive disease (ED) SCLC)
• • patients ≥ 18 years
• Exclusion Criteria:
• • - Due to the non-interventional design of the registry there are no specific exclusion criteria.